Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set.

Sabina CicirielloGeoffrey Owen LittlejohnTamas TreuerKathryn A GibsonEwa HaladyjPeter YoussefPaul Bird Catherine O'SullivanTegan SmithClaire T Deakinnull null

Published in: ACR open rheumatology (2023)

In this comparative analysis, treatment persistence up to 24 months was significantly longer for first-line BARI compared with TNFi, but the effect size of 1.00 month is not clinically meaningful. There was no difference in persistence for BARI monotherapy versus combination therapy.

Keyphrases

combination therapy
randomized controlled trial
machine learning
study protocol
artificial intelligence